Spherix reports Naturlose Ph III results

USA-based Spherix Inc has announced results from an ongoing Phase III clinical trial for its natural diabetes treatment Naturlose.

The natural food-grade sugar has been found to reduce the spikes of serum glucose that follow consumption of food in patients with diabetes, according to a study published in the journal, Diabetes, Obesity and Metabolism. The product is available in chewable, fast-disolving oral and powdered formulations and is taken along with meals. Spherix will be seeking Food and Drug Administration approval of the product as treatment for diabetes upon completion of the trial.

The company has also reported on market research for the product conducted through focus groups of diabetes sufferers and physicians. The firm notes those surveyed valued the safety of a natural formulation and found the taste pleasant.